SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Public ClinicalTrials.gov record NCT04033367. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD). Secondary Objectives: To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation. To continue to assess the safety and tolerability throughout the study.
Study identification
- NCT ID
- NCT04033367
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 188 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 21, 2019
- Primary completion
- Oct 5, 2021
- Completion
- Oct 5, 2021
- Last update posted
- Sep 16, 2025
2019 – 2021
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number :8400012 | North Little Rock | Arkansas | 72117 | — |
| Investigational Site Number :8400002 | Redwood City | California | 94063 | — |
| Investigational Site Number :8400001 | Rolling Hills Estates | California | 90274 | — |
| Investigational Site Number :8400013 | Colorado Springs | Colorado | 80907 | — |
| Investigational Site Number :8400005 | Denver | Colorado | 80230 | — |
| Investigational Site Number :8400003 | Sarasota | Florida | 34239 | — |
| Investigational Site Number :8400007 | Medford | Oregon | 97504 | — |
| Investigational Site Number :8400008 | Charleston | South Carolina | 29407 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
Recently updated Atopic Dermatitis trials
Other public records listing Atopic Dermatitis. Sorted by last update posted; newest first. Not a recommendation.
- NCT04504955: CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness Recruiting
- NCT07783425: A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema Not yet recruiting
- NCT06718101: A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis Active, not recruiting
- NCT07643766: A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis Recruiting
- NCT07748169: An Observational Study of Patients With Dermatologic Disease Recruiting
- NCT07746427: Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04033367, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 16, 2025 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04033367 live on ClinicalTrials.gov.